These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

394 related items for PubMed ID: 31101091

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Comparison of second-line therapy in IVIg-refractory Kawasaki disease: a systematic review.
    Crayne CB, Mitchell C, Beukelman T.
    Pediatr Rheumatol Online J; 2019 Nov 27; 17(1):77. PubMed ID: 31775898
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [Steroid pulse therapy].
    Miura M.
    Nihon Rinsho; 2014 Sep 27; 72(9):1631-5. PubMed ID: 25518414
    [Abstract] [Full Text] [Related]

  • 6. Corticosteroid pulse combination therapy for refractory Kawasaki disease: a randomized trial.
    Ogata S, Ogihara Y, Honda T, Kon S, Akiyama K, Ishii M.
    Pediatrics; 2012 Jan 27; 129(1):e17-23. PubMed ID: 22144699
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Infliximab as a second-line therapy for children with refractory Kawasaki disease: A systematic review and meta-analysis of randomized controlled trials.
    Kabbaha S, Milano A, Aldeyab MA, Thorlund K.
    Br J Clin Pharmacol; 2023 Jan 27; 89(1):49-60. PubMed ID: 36169097
    [Abstract] [Full Text] [Related]

  • 9. Treatment of immunoglobulin-resistant kawasaki disease: a Bayesian network meta-analysis of different regimens.
    Pan Y, Fan Q, Hu L.
    Front Pediatr; 2023 Jan 27; 11():1149519. PubMed ID: 37520059
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease.
    Burns JC, Best BM, Mejias A, Mahony L, Fixler DE, Jafri HS, Melish ME, Jackson MA, Asmar BI, Lang DJ, Connor JD, Capparelli EV, Keen ML, Mamun K, Keenan GF, Ramilo O.
    J Pediatr; 2008 Dec 27; 153(6):833-8. PubMed ID: 18672254
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The Clinical Utility and Safety of a New Strategy for the Treatment of Refractory Kawasaki Disease.
    Ebato T, Ogata S, Ogihara Y, Fujimoto M, Kitagawa A, Takanashi M, Ishii M.
    J Pediatr; 2017 Dec 27; 191():140-144. PubMed ID: 29173297
    [Abstract] [Full Text] [Related]

  • 17. Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial.
    Burns JC, Roberts SC, Tremoulet AH, He F, Printz BF, Ashouri N, Jain SS, Michalik DE, Sharma K, Truong DT, Wood JB, Kim KK, Jain S, KIDCARE Multicenter Study Group.
    Lancet Child Adolesc Health; 2021 Dec 27; 5(12):852-861. PubMed ID: 34715057
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Delayed intravenous immunoglobulin treatment increased the risk of coronary artery lesions in children with Kawasaki disease at different status.
    Qiu H, He Y, Rong X, Ren Y, Pan L, Chu M, Wu R, Shi H.
    Postgrad Med; 2018 May 27; 130(4):442-447. PubMed ID: 29745742
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.